Circulating Tumor Cells in Patients With Castration-Resistant Prostate Cancer Baseline Values and Correlation With Prognostic Factors

Cancer Epidemiology Biomarkers and Prevention - United States
doi 10.1158/1055-9965.epi-08-1173
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Circulating Tumor Cell Analysis in Patients With Progressive Castration-Resistant Prostate Cancer

Clinical Cancer Research
Cancer ResearchOncology
2007English

AR Splice Variants in Circulating Tumor Cells of Patients With Castration‐resistant Prostate Cancer: Relation With Outcome to Cabazitaxel

Molecular Oncology
Cancer ResearchMedicineOncologyGeneticsMolecular Medicine
2019English

Isolation and Genomic Analysis of Circulating Tumor Cells From Castration Resistant Metastatic Prostate Cancer

BMC Cancer
Cancer ResearchOncologyGenetics
2012English

TMPRSS2-ERG Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated With Abiraterone Acetate

European Urology
Urology
2011English

Docetaxel Rechallenge in Patients With Castration-Resistant Prostate Cancer — A Review

European Oncology and Haematology
OncologyHematology
2012English

Prognostic Role of Tif1γ Expression and Circulating Tumor Cells in Patients With Breast Cancer

Molecular Medicine Reports
OncologyGeneticsMolecular BiologyBiochemistryCancer ResearchMolecular Medicine
2019English

Targeting Cancer Stem Cells in Castration-Resistant Prostate Cancer

Clinical Cancer Research
Cancer ResearchOncology
2015English

Circulating Tumor Cells as a Prognostic Factor in Patients With Small Cell Lung Cancer

Oncology Letters
Cancer ResearchOncology
2014English

ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer

Cancer Cell
Cancer ResearchOncologyCell Biology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy